PPARG and chronic myelogenous leukemia, BCR-ABL1 positive: While the LD regulatory effects of PPARγ, specifically, have not been explored in CML, several clinical studies have examined whether the therapeutic activation of PPARγ could improve the molecular response in CML [71,72,73,74].